Q3 Earnings Forecast for CG Oncology Issued By HC Wainwright

CG Oncology, Inc. (NASDAQ:CGON) – Equities researchers at HC Wainwright raised their Q3 2025 EPS estimates for shares of CG Oncology in a research note issued on Monday, August 11th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.55) for the quarter, up from their prior estimate of ($0.58). HC Wainwright has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for CG Oncology’s Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($2.13) EPS, FY2026 earnings at ($2.29) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at $0.08 EPS and FY2029 earnings at $1.85 EPS.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Friday, August 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.05). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 19.37%.

A number of other analysts also recently weighed in on CGON. Wall Street Zen downgraded shares of CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Morgan Stanley increased their price target on shares of CG Oncology from $52.00 to $56.00 and gave the company an “overweight” rating in a report on Tuesday, June 17th. The Goldman Sachs Group raised shares of CG Oncology to a “strong-buy” rating and set a $40.00 price target for the company in a report on Thursday, July 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 price target on shares of CG Oncology in a report on Monday, April 28th. Finally, Royal Bank Of Canada reduced their price target on shares of CG Oncology from $68.00 to $53.00 and set an “outperform” rating for the company in a report on Wednesday, July 16th. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $55.30.

CG Oncology Price Performance

Shares of CG Oncology stock opened at $25.70 on Thursday. CG Oncology has a fifty-two week low of $14.80 and a fifty-two week high of $40.47. The firm has a fifty day moving average price of $26.16 and a two-hundred day moving average price of $25.51. The company has a market cap of $1.96 billion, a PE ratio of -14.52 and a beta of 0.87.

Hedge Funds Weigh In On CG Oncology

Several institutional investors have recently added to or reduced their stakes in the company. Winthrop Capital Management LLC acquired a new stake in CG Oncology in the 2nd quarter valued at about $38,000. GF Fund Management CO. LTD. acquired a new stake in CG Oncology in the 4th quarter valued at about $41,000. CWM LLC increased its position in CG Oncology by 3,957.7% in the 1st quarter. CWM LLC now owns 2,110 shares of the company’s stock valued at $52,000 after acquiring an additional 2,058 shares in the last quarter. GAMMA Investing LLC increased its position in CG Oncology by 1,051.0% in the 1st quarter. GAMMA Investing LLC now owns 2,302 shares of the company’s stock valued at $56,000 after acquiring an additional 2,102 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in CG Oncology by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company’s stock valued at $77,000 after acquiring an additional 398 shares in the last quarter. 26.56% of the stock is owned by institutional investors.

Insider Activity at CG Oncology

In other news, Director Leonard E. Post sold 2,000 shares of the firm’s stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $28.00, for a total transaction of $56,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 7.40% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.